Supreme Court Declines to Hear Medicare Drug Price Negotiation Challenge

Supreme Court Declines to Hear Medicare Drug Price Negotiation Challenge

This week, the Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program established by the 2022 Inflation Reduction Act (IRA). The program established, for the first time, the ability of the federal government to directly negotiate prices for drugs offered under Medicare’s Part D prescription drug coverage. The Court’s refusal to consider these manufacturers’ appeals leaves in place a g…